Calidi Biotherapeutics, Inc. CLDI PHARMA
Company Overview
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -98.56% |
| 6 Months: | -76.95% |
| 3 Months: | -51.79% |
| 1 Month: | -16.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.20 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 98.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CLDI Calidi Biotherapeutics, Inc. PHARMA | 1.35 | -0.04 | $3.49M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -83.30K | -1.09M | -528.86K | -361.62K | -6.99M | -5.41M | -6.54M | -7.22M | -6.75M | -5.77M | -5.23M | -5.06M | -5.66M | -5.05M | -4.19M |
| Net Income | -83.30K | -823.29K | -7.74M | -4.58M | -5.36M | -6.46M | -12.50M | -2.02M | -7.22M | -5.77M | -5.05M | -4.99M | -5.71M | -5.15M | -4.11M |
| Diluted EPS | - | - | - | - | -0.63 | -0.75 | -14.24 | -1.41 | -2.03 | -16.75 | -7.75 | -2.21 | -1.99 | -2.21 | -0.43 |
| R&D Expense | - | - | - | - | 1.95M | 2.62M | 3.18M | 3.25M | 2.74M | 2.17M | 2.15M | 2.42M | 2.59M | 2.36M | 2.59M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 45.00K | - | - | - |
| Operating Income | -23.13M | -28.99M | -21.78M | -20.24M |
| Net Income | -25.43M | -29.22M | -22.14M | -19.91M |
| Diluted EPS | 2.99 | -17.33 | -35.70 | -5.95 |
| R&D Expense | 7.26M | 13.01M | 8.88M | 9.74M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 231.77M | 2.60M | 10.02M | 14.18M | 8.86M |
| Total Equity | 0 | -31.61M | -50.44M | -8.23M | 1.53M | 3.76M |
| Cash & Equivalents | - | 1.06M | - | - | 9.60M | - |
| Long Term Debt | - | - | - | 2.06M | 600.00K | 600.00K |
| Total Liabilities | - | 16.45M | 43.44M | 18.25M | 12.21M | 5.10M |
| Current Liabilities | - | 410.99K | 42.99M | 10.23M | 9.50M | 3.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -13.21M | -26.98M | -19.69M | -21.29M |
| Investing Cash Flow | -494.00K | -478.00K | -16.00K | -170.00K |
| Financing Cash Flow | 12.09M | 29.04M | 27.36M | 17.46M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -51,395.6% | - | - | - |
| Net Margin % | -56,504.4% | - | - | - |
| ROE % | 50.4% | 354.8% | -1,443.5% | -529.6% |
| ROCE % | 57.3% | 13,611.3% | -464.7% | -411.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.28% | 7.16K | $7.88K |
| 2 | HighTower Advisors, LLC | 0.20% | 5.22K | $5.74K |
| 3 | Jane Street Group, LLC | 0.13% | 3.39K | $3.73K |
| 4 | Independent Advisor Alliance | 0.11% | 2.81K | $3.09K |
| 5 | Rs Crum Inc. | 0.10% | 2.70K | $2.97K |
| 6 | Arax Advisory Partners | 0.09% | 2.33K | $2.57K |
| 7 | Private Advisor Group, LLC | 0.07% | 1.88K | $2.06K |
| 8 | Vanguard Capital Management LLC | 0.06% | 1.59K | $1.75K |
| 9 | Belpointe Asset Management LLC | 0.05% | 1.25K | $1.37K |
| 10 | Northern Trust Corporation | 0.04% | 1.11K | $1.22K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLDI
Calidi shareholders will get one share for every 16 held - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNMnZJTUFiSVVCSmlFZXhZYmIxWXRyRlpmYWxGZjlnYXR4SWh5UFlMNnR1THNLWk1rZl9adE41eFN0Yk1WNlpsbWVERVBzVUEtYU8xdWNkTUc0U3FNRXRJTXY3VEZIczdrcmh3R3BqYUxFTk1WMTNSd3F1SFJhNEUxcGc5MlRRWC0wX0R4c0…
CLDI - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFAxQnk3QzViY0xnY280akY3R1VKUHVoeG9qZ1RzNjlaR3ZKc0dUaGJtQXVLRlFxNmNsRklzM1plcy0xTlUzclE?oc=5" target="_blank">CLDI</a> <font color="#6f6f6f">Finviz</font>…
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMikwJBVV95cUxNY0dHYzdYbTREaldWS0llN3JMekZkOFpabDJSbUthbENrU0hmNHNkUnI4cGs4ZnJXLXZMenZFLUVLVkRwbmZJQmRnV3l6dWRUaF9YZnF0UHpHWlJWazFmSTQyOUZXN3ZLaUNiT3c0Rk1aRzlSTTdFZzRSdDc5cWRJU1ZiWDN4Qk44azNzS2…
Calidi Biotherapeutics To Carry Out 1-for-16 Reverse Stock Split On July 31st, 2026 - Moomoo
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOMVdpcUl1eDd4S3FPcXdpblJHMkIwSFU0LXFySDgyQ0NTcjhnSnJrQmRVRWxKdnVUT3JDNE1TdC1oSWQ2TGJQX0xXeHNGR0F3eUgwZXJOMlppSEhSN1NXbnh2TVBoOFhMdjZ3eFhrQTZMWXd3RGhjRFNPRmF0QjREY29jVTZFelFqRE1FQT…
Calidi highlights new EpCam-targeting T-cell engager data - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNaGJrVUxZMGJndHlQaWVQc2I2dkFMUFE5V055a2g4WFVudkN1Wi1xVG5LckhoSkN3NmdnUHJ6bDFSWkg3SGpnNUhwZXF6ZC1HWmhaVzJ2WElpM1d2cHVzSzZ0QzZFaVM2bkNXMkkxZTk4LUViYlhORHZKQ3ljTllRblMzajFVbVp6dzZhb2…
Calidi Biotherapeutics Inc. (NYSE: CLDI) Share Price, CLDI Stock News, CLDI Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE8wVldMM2VVaWo1Yzh4WG1na2V0a19Na1ZqMGJnbUJaMndlb05ENi0xQjNBUmtJdFpac215LUtNeU10OXFGQnpWQmR1NGtxTmIzdng0?oc=5" target="_blank">Calidi Biotherapeutics Inc. (NYSE: CLDI) Share Price, C…
CLDI — Frequently Asked Questions
What is the current share price of Calidi Biotherapeutics, Inc. (CLDI)?
As of 2026-09-19 21:16 PDT, Calidi Biotherapeutics, Inc. (CLDI) trades at $1.35 on NYSE American. Its 52-week range is $1.27 to $93.76.
What is the market capitalisation of CLDI?
Calidi Biotherapeutics, Inc. (CLDI) has a market capitalisation of $3.49M on NYSE American.
What is the P/E ratio of CLDI?
CLDI trades at a trailing price-to-earnings (P/E) ratio of -0.04. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.91.
Is CLDI a good stock to buy?
This page provides a data-driven analysis of Calidi Biotherapeutics, Inc. (CLDI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.